Scholarly article on N-Benzyloxycarbonyl-threo-N,β-dimethyl-L-leucin 20544-89-2 from Journal of the American Chemical Society p. 875 - 879

DOI: 10.1021/ja00784a041

Source and publish data:

Journal of the American Chemical Society p. 875 - 879 (1973)

Update date:2022-08-04

Topics:

Authors:

Sheehan,J.C.

Ledis,S.L.

Read Full Text PDF DownLoad Join now for total 90,000,000 free articles

Article abstract of DOI:10.1021/ja00784a041

Full text of DOI:10.1021/ja00784a041

Products guided by the article

Product name:N-Benzyloxycarbonyl-threo-N,β-dimethyl-L-leucin

Cas No:20544-89-2

R&D Labs maybe for 20544-89-2

Tianjin Tongde Biological Technology Co., Ltd.

Contact:86-22-23309138

Address:Room 402, bulidingE3 Detection certification park, XiQingDistrict, Tianjin City
Zhejiang Chemicals Import & Export Corporation (ZHECHEM)

Contact:+86-571-87046953

Address:No. 37, Qingchun Road
Radiant Pharma & Tech Company

Contact:+86-511-88790000

Address:338 North Yushan Rd, Zhenjiang, Jiangsu 212016
Chongqing KonAo Health Co.,Ltd

Contact:13687578375

Address:wuhan hubei china
Shenyang Mole pharmaceutical Technology Development Co.,Ltd

Contact:+86-24-31204918/13889278616

Address:No.44, wanliutang road, shenhe District of Shenyang

Relevant to this article

Preparation of enol ethers by carbonyl olefination utilizing an alkoxymethyl chloride-titanocene(II) system

Doi:10.1016/j.tetlet.2003.09.013
(2003)
Doi:10.1039/j29680001036
(1968)
Discovery of a novel benzyloxyisoquinoline derivative with potent anti- Helicobacter pylori activity

Doi:10.1016/S0960-894X(98)00335-7
(1998)
Doi:10.1063/1.1747272
(1949)
Structure-activity relationships of a series of 1-substituted-4-methylbenzimidazole neuropeptide Y-1 receptor antagonists

Doi:10.1016/S0960-894X(98)00048-1
(1998)
Design of plasma kallikrein inhibitors: Functional and structural requirements of plasma kallikrein inhibitors

Doi:10.1248/cpb.46.452
(1998)

Article Doi

DOI: 10.1021/ja00784a041